Connection
Jeffrey Kern to Antineoplastic Agents
This is a "connection" page, showing publications Jeffrey Kern has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.049 |
|
|
|
-
Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005 Apr 15; 103(8):1670-5.
Score: 0.027
-
Johnson EA, Klimstra DS, Herndon JE, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20(5-6):686-92.
Score: 0.022